Zanwar Saurabh, Jain Punit, Gokarn Anant, Devadas Santhosh Kumar, Punatar Sachin, Khurana Sachin, Bonda Avinash, Pruthy Ritesh, Bhat Vivek, Qureshi Sajid, Khattry Navin
Department of Medical Oncology, ACTREC, Tata Memorial Center, Mumbai, India.
Department of Hematology and Bone Marrow Transplant, Apollo Hospitals, Navi Mumbai, India.
Transpl Infect Dis. 2019 Feb;21(1):e13017. doi: 10.1111/tid.13017. Epub 2018 Nov 19.
Central venous catheters (CVCs) represent a significant source of infection in patients undergoing hematopoietic stem cell transplantation and can add to the cost of care, morbidity, and mortality. Organisms forming biofilms on the inner surface of catheters require a much higher local antibiotic concentration to clear the pathogen growth. Antibiotic lock therapy (ALT) represents one such strategy to achieve such high intraluminal concentrations of antibiotics and can facilitate catheter salvage. Patients with catheter colonization (CC) or hemodynamically stable catheter-related bloodstream infection (CRBSI) received ALT per institutional policy. We analyzed the incidence of CC and CRBSI and salvage rate of tunneled CVCs (Hickman) with ALT in patients undergoing hematopoietic stem cell transplant in this retrospective study. Catheter colonization was noted in 9.8% and CRBSI in 10.7% patients. Gram-negative bacilli (GNB) accounted for 45% and 83% of isolates in CC and CRBSI, respectively. In patients with CRBSI, the rate of catheter salvage with the use of ALT in addition to systemic antibiotics was 86% compared to 55% in patients with systemic antibiotics use only (P = 0.06). There was no CRBSI related mortality, and no increase in resistant strains was noted at subsequent CRBSI. In conclusion, ALT represents an important strategy for catheter salvage, especially for gram-negative infections, in a carefully selected patient population.
中心静脉导管(CVCs)是接受造血干细胞移植患者感染的重要来源,会增加护理成本、发病率和死亡率。在导管内表面形成生物膜的微生物清除病原体生长需要更高的局部抗生素浓度。抗生素封管疗法(ALT)是实现如此高管腔内抗生素浓度的一种策略,可促进导管挽救。根据机构政策,导管定植(CC)或血流动力学稳定的导管相关血流感染(CRBSI)患者接受ALT治疗。在这项回顾性研究中,我们分析了接受造血干细胞移植患者中CC和CRBSI的发生率以及使用ALT治疗隧道式CVC(Hickman导管)的挽救率。9.8%的患者出现导管定植,10.7%的患者出现CRBSI。革兰氏阴性杆菌(GNB)分别占CC和CRBSI分离株的45%和83%。在CRBSI患者中,除全身使用抗生素外,联合使用ALT的导管挽救率为86%,而仅使用全身抗生素的患者为55%(P = 0.06)。未出现与CRBSI相关的死亡,后续CRBSI时未发现耐药菌株增加。总之,在精心挑选的患者群体中,ALT是导管挽救的重要策略,尤其是对于革兰氏阴性菌感染。